ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Octreotide

Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.

Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.

Drug pageOctreotide: every studyMany companies study it; this page follows only the 30 they lead. All 121 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 17, 200230 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only210 open or runningphase 4since Dec 17, 2002Nov 2, 1999none ahead
Keenova Therapeuticsits history only40 open or runningphase 3since Sep 30, 2008Sep 30, 2008none ahead
Chiesi Farmaceutici30 open or runningphase 3since Aug 5, 2011Aug 5, 2011none ahead
Ambrilia Biopharmaits history only10 open or runningphase 3since Mar 21, 2008Mar 21, 2008none ahead
Dauntless Pharmaceuticalsits history only10 open or runningphase 1since Jan 17, 2017Jan 17, 2017none ahead

Also a collaborator on its studies: Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chiesi Farmaceutici only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2011First study: phase 3 study in AcromegalyFirst studyNCT01412424 · 155 enrolled · United States, Germany, Hungary and more
  2. Jan 28, 2016Phase 3 study in AcromegalyNCT02685709 · 146 enrolled · United States, Austria, France and more
  3. Aug 10, 2017Phase 3 study in AcromegalyNCT03252353 · 56 enrolled · United States, Australia, Bulgaria and more

TargetBeta

“Somatostatin receptor agonist”ChEMBL 37, by rule

Studies

All 3 Chiesi Farmaceutici leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03252353Acromegaly · United States, Australia, Bulgaria and more3UNKNOWNJun 13, 201956
NCT02685709Acromegaly · United States, Austria, France and more3CompletedOct 2020146
NCT01412424Acromegaly · United States, Germany, Hungary and more3CompletedMay 2014155

How it is read

Names in the registry

  • “Octreotide”, 9 entries
  • “Sandostatin LAR Depot”, 3 entries
  • “Octreotide LAR”, 3 entries
  • “Sandostatin LAR”, 3 entries
  • “Octreotide capsules”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.